Qiagen

Decent end to 2024

06/02/25 -"Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. While mid-single-digit growth is ..."

PDF page sample
Pages
62
Language
English
Published on
06/02/25
Download
You may also be interested by these reports :
31/10/25
Drägerwerk’s delivered solid Q3 2025 numbers. Revenue rose 10.1% to €833 million, driving a substantial 370bps EBIT margin expansion to 6.8%. This, ...
30/10/25
Amplifon’s Q3 results did not meet the company-compiled consensus. Sales growth was supported by strong performance in the Americas and a recovery in ...
29/10/25
We have broadly maintained our 2025 estimates, which remain in line with the 9M trading update and reconfirmed FY guidance. We have adopted a more ...
29/10/25
Emeis reported in-line Q3 revenue figures and reiterated its 2025 and mid-term objectives. This should be well received by the market, especially ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO